Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline ...

Study finds sensory cells that detect tissue damage, irritants also rein in harmful immune responses to protect the lungs ...

AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

That’s the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent ...

A large trial in a primary care setting found daily emollient use to be safe, feasible, and effective in reducing atopic ...

Enanta Pharmaceuticals (NASDAQ:ENTA) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE) and some of ...

AbbVie announced an update on their ongoing clinical study. The pharmaceutical giant is conducting a Phase 1b clinical study ...

DelveInsight's Personal Care Contract Manufacturing Market Insights report provides the current and forecast market analysis, ...